---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-028046"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:52:54.777458+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics reports FY2025 net loss of $12.6M; APR-1051 shows two partial responses

## Summary
- Cash and equivalents $14.6M at Dec 31, 2025; plus Jan 2026 private placement of $5.6M funds operations into Q1 2027.
- Net loss $12.6M ($1.93/share) for FY2025 vs $13.0M ($2.35/share) in FY2024; R&D spend down to $7.0M from $9.4M.
- APR-1051 (WEE1 inhibitor) yields two unconfirmed partial responses in PPP2R1A-mutated endometrial cancer; dose escalation ongoing at 220 mg.
- ATRN-119 (ATR inhibitor) RP2D set at 1,100 mg; monotherapy enrollment paused, exploring combination studies.
- Appointed Eugene Kennedy, MD, as Chief Medical Advisor in February 2026 to support next phase of development.

## SEC filing metadata
- accession: 0001104659-26-028046
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465926028046/0001104659-26-028046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465926028046/apre-20260316x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-028046
- JSON: https://secwatch.observer/filing/0001104659-26-028046.json
- Plain text: https://secwatch.observer/filing/0001104659-26-028046.txt

## Key facts
- Earnings Releases
  Aprea Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Result: reported results
  source text: On March 16, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465926028046/0001104659-26-028046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.